ADL Amdl,

TUSTIN, Calif., Nov. 9 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), announced today that it has completed its pre-IDE for the use of its DR-70(R) test kit in monitoring colon cancer patients. "We are looking forward to presenting this data, which we believe answers the questions previously asked by the U.S. Food & Drug Administration. We are attempting to coordinate a meeting with the FDA in mid-December," said Gary Dreher, CEO. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc. is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its additional products can be obtained at http://www.amdl.com/. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright